Ozempic, Wegovy & GLP-1 Drugs — What Fertility Patients Need to Know

GLP-1 receptor agonists — the class of drugs that includes semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro) — have transformed the treatment of obesity and type 2 diabetes in recent years. These medications work by mimicking the action of glucagon-like peptide-1, a gut hormone that regulates appetite, blood sugar, and gastric emptying. They are now prescribed widely, including to many women with PCOS who are using them to manage weight and insulin resistance.

At Mother Hospitals & IVF Center in Hyderabad, Dr. E. Prashanthi Reddy is seeing a growing number of fertility patients who are on — or recently stopped — GLP-1 medications. This article explains what these drugs do, how they intersect with fertility treatment, and the critical decisions patients must make before beginning IVF or attempting natural conception.

How GLP-1 Drugs Work and Why PCOS Patients Use Them

GLP-1 receptor agonists were originally developed for type 2 diabetes but have become mainstream weight management tools following robust trial data. They act on multiple fronts:

• Appetite suppression: They slow gastric emptying and act on hunger centres in the brain, significantly reducing caloric intake.
• Blood sugar regulation: They stimulate insulin release in response to meals and suppress glucagon, improving glycaemic control.
• Weight loss: In clinical trials, semaglutide at weight-management doses produced an average body weight reduction of 15–17%, and tirzepatide up to 20–22%.

For women with PCOS — a condition characterised by insulin resistance in approximately 70% of affected individuals — these benefits are particularly relevant. Excess weight worsens insulin resistance, which in turn elevates androgen levels, suppresses ovulation, and drives the metabolic complications of PCOS. Addressing weight and insulin resistance is therefore at the heart of PCOS management.

The Potential Benefits for PCOS and Fertility

Several small clinical studies have demonstrated meaningful reproductive benefits of GLP-1 drugs in women with PCOS:

• Restoration of ovulation: In overweight women with anovulatory PCOS, significant weight loss via GLP-1 drugs has been shown to restore spontaneous ovulation in some cases — without any fertility medication.
• Improved response to ovulation induction: Women who achieve weight reduction before starting fertility treatment typically respond better to ovulation induction drugs such as letrozole or gonadotrophins.
• Reduction in androgen levels: Lower body fat reduces peripheral androgen production, which can improve follicular development.
• Lower OHSS risk: Women with PCOS undergoing IVF are at elevated risk of ovarian hyperstimulation syndrome. Reducing metabolic dysfunction before treatment may lower this risk.

The Critical Decision: When to Stop Before IVF or Conception

This is the most important section of this article, and it is where many patients need clear guidance. The consensus among reproductive endocrinologists and fertility specialists is as follows:

Stop at Least 2 Months Before Egg Retrieval

Semaglutide has a biological half-life of approximately one week, meaning it takes several weeks to clear from the body fully. However, the standard recommendation is to discontinue semaglutide and other GLP-1 drugs at least 8 weeks (2 months) before egg retrieval in IVF cycles. Some guidance suggests stopping even earlier — particularly for higher doses.

For tirzepatide (Mounjaro), which also has a long half-life, a similar 2-month washout period is generally recommended, though specific guidelines continue to evolve.

Why the Washout Period Matters

• Fetal safety unknown: GLP-1 receptor agonists are classified as Category X-equivalent in pregnancy based on animal studies showing fetal harm. There are insufficient human data to determine safe exposure levels during early embryo development.
• Embryo transfer risk: If a woman becomes pregnant shortly after an embryo transfer, GLP-1 drug residue in her system could theoretically reach the developing embryo. The washout period minimises this risk.
• Nausea interference: GLP-1 drugs commonly cause nausea and vomiting, particularly at higher doses. This can make it difficult for patients to tolerate oral fertility medications or maintain adequate nutrition during stimulation.
• Gastric motility changes: These drugs slow gastric emptying, which can affect the absorption of oral medications used during IVF cycles, including progesterone and oestrogen tablets.

What About Natural Conception?

If you are trying to conceive naturally and ovulation has been restored with the help of GLP-1 drugs, you should still discontinue the medication before attempting conception. If you discover you are pregnant while still taking a GLP-1 drug, stop the medication immediately and notify your doctor. The evidence on outcomes in such cases is limited and reassurance comes only from stopping as early as possible.

What to Discuss With Your Fertility Doctor

If you are currently on or have recently taken a GLP-1 receptor agonist and are planning fertility treatment, bring the following to your consultation:

• The specific medication name and dose (Ozempic 0.5mg/1mg/2mg, Wegovy 2.4mg, Mounjaro, or generic semaglutide)
• When you started the medication and when you stopped (or if you are still taking it)
• Your current weight and any weight lost on the medication
• Whether your cycles have changed since starting the medication
• Any other medications or supplements you are taking
• Your most recent metabolic blood work (fasting insulin, HbA1c, lipid profile)

GLP-1 Drugs and Their Interaction With Fertility Medications

Beyond safety during pregnancy, there are potential pharmacological interactions worth knowing about:

• Gonadotrophins (FSH/LH injections): No direct drug interactions, but nausea from GLP-1s can make self-injection more difficult and reduce patient compliance.
• Metformin: Many PCOS patients take both metformin and a GLP-1 drug. During IVF, your doctor will advise whether to continue metformin — it is sometimes kept during stimulation to reduce OHSS risk in PCOS patients.
• Oral progesterone/oestrogen: Altered gastric emptying from GLP-1 drugs may affect absorption. Stopping the GLP-1 medication eliminates this variable.
• Letrozole or clomiphene for ovulation induction: No direct interaction, but again, the medication should be discontinued before beginning ovulation induction cycles for conception purposes.

The Weight Regain Question

One of the practical concerns patients raise is: "If I stop Ozempic, I'll regain the weight I lost. How do I manage this during IVF?" This is a valid concern. GLP-1 drug discontinuation is associated with weight regain in many patients. However:

• The metabolic improvements gained during weight loss — better insulin sensitivity, lower androgen levels, restored ovulation — often persist for months after stopping.
• A structured diet and exercise plan during the 2-month washout period can help maintain weight.
• The IVF cycle itself is typically 4–6 weeks, so the total period off GLP-1 medication before a pregnancy is confirmed is usually 3–4 months — manageable for most patients.
• After a successful pregnancy and delivery, GLP-1 drugs can be restarted under medical supervision if required.

Frequently Asked Questions